Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.

Abstract

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials.

• Authors: Cihan Yurdaydin, Zaigham Abbas, Maria Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward J Gane, Robert G Gish, Jeffrey S Glenn, Saeed Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael Manns, Raymundo Parana, Mario Rizzetto, Stephan Urban, Heiner Wedemeyer, Hepatitis Delta International Network (HDIN)
• Journal: Journal of hepatology (J Hepatol) Vol. 70 Issue 5 Pg. 1008-1015 (05 2019) ISSN: 1600-0641 [Electronic] Netherlands
• PMID: 30982526 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2018. Published by Elsevier B.V.

Chemical References

• Biomarkers
• Hepatitis B Surface Antigens
• Lipopeptides
• Nucleic Acids
• Piperidines
• Polymers
• Pyridines
• REP 2139
• RNA, Viral
• myrcludex-B
• lonafarnib

Topics

• Biomarkers
• Clinical Trials as Topic
• Hepatitis B Surface Antigens (analysis)
• Hepatitis D, Chronic (drug therapy, pathology)
• Humans
• Lipopeptides (therapeutic use)
• Liver (pathology)
• Nucleic Acids (therapeutic use)
• Piperidines (therapeutic use)
• Polymers (therapeutic use)
• Pyridines (therapeutic use)
• RNA, Viral (analysis)
• Treatment Outcome